Year Published
- 2008 (0)
- 2009 (0)
- 2010 (0)
- 2011 (0)
- 2012 (0)
- 2013 (0)
- 2014 (0)
- 2015 (0)
- 2016 (1) Apply 2016 filter
- 2017 (0)
- 2018 (0)
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (0)
- Literature Review (1) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- East Africa Region and Selected Countries (0)
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (0)
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (1) Apply ASTI filter
- (-) Remove FAOSTAT filter FAOSTAT
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove Aid & Other Development Finance filter Aid & Other Development Finance
- (-) Remove Global filter Global
- (-) Remove FAOSTAT filter FAOSTAT
This research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. We summarize the public good characteristics of R&D for agriculture in general and for commodity and subsistence crops in particular, as well as R&D for health in general and for neglected diseases in particular, with a focus on Sub-Saharan Africa and South Asia. Finally, we present rationales for which funders are predicted to fund which R&D types based on these funder and R&D characteristics. We then compile available statistics on funding for agricultural and health R&D from private, public and philanthropic sources, and compare trends in funding from these sources against expectations. We find private agricultural R&D spending focuses on commodity crops (as expected). However contrary to expectations we find public and philanthropic spending also goes largely towards these same crops rather than staples not targeted by private funds. For health R&D private funders similarly concentrate on diseases with higher potential financial returns. However unlike in agricultural R&D, in health R&D we observe some specialization across funders – especially for neglected diseases R&D - consistent with funders’ expected relative advantages.